Cintredekin Besudotox

Precision NeuroMed Earns FDA Orphan Drug Status for GBM Therapy

REDWOOD CITY, Calif., Oct. 7, 2025 — Precision NeuroMed (PNM), a clinical-stage biotechnology company advancing next-generation drug delivery technologies...

By cGxPwire Editor
October 7, 2025

We work Hard to get you posted with latest updates

Unwrap our new Directory

Cintredekin Besudotox

Precision NeuroMed Earns FDA Orphan Drug Status for GBM Therapy